Tomoji Maeda

Dr. Tomoji Maeda


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
CCCheng-Chung Chang
Cheng-Chung Chang
HTHsi-Kai Tsou
Hsi-Kai Tsou
HCHsu-Hsin Chang
Hsu-Hsin Chang
LCLong Yi Chan
Long Yi Chan
GZGuan-Yu Zhuo
Guan-Yu Zhuo
Chin-Yu LinChin-Yu Lin
Chin-Yu Lin
Vertebral disc degenerative disease (DDD) affects millions of people worldwide and is a critical factor leading to low back and neck pain and consequent disability. Currently, no strategy has addressed curing DDD from fundamental aspects, because the pathological mechanism leading to DDD is still controversial. One possible mechanism points to the homeostatic status of extracellular matrix (ECM) anabolism, and catabolism in the disc may play a vital role in the disease’s progression. If the damaged disc receives an abundant amount of cartilage, anabolic factors may stimulate the residual cells in the damaged disc to secrete the ECM and mitigate the degeneration process. To examine this hypothesis, a cartilage anabolic factor, Runx1, was expressed by mRNA through a sophisticated polyamine-based PEG-polyplex nanomicelle delivery system in the damaged disc in a rat model. The mRNA medicine and polyamine carrier have favorable safety characteristics and biocompatibility for regenerative medicine. The endocytosis of mRNA-loaded polyplex nanomicelles in vitro, mRNA delivery efficacy, hydration content, disc shrinkage, and ECM in the disc in vivo were also examined. The data revealed that the mRNA-loaded polyplex nanomicelle was promptly engulfed by cellular late endosome, then spread into the cytosol homogeneously at a rate of less than 20 min post-administration of the mRNA medicine. The mRNA expression persisted for at least 6-days post-injection in vivo. Furthermore, the Runx1 mRNA delivered by polyplex nanomicelles increased hydration content by ≈43% in the punctured disc at 4-weeks post-injection (wpi) compared with naked Runx1 mRNA administration. Meanwhile, the disc space and ECM production were also significantly ameliorated in the polyplex nanomicelle group. This study demonstrated that anabolic factor administration by polyplex nanomicelle-protected mRNA medicine, such as Runx1, plays a key role in alleviating the progress of DDD, which is an imbalance scenario of disc metabolism. This platform could be further developed as a promising strategy applied to regenerative medicine.

1 April 2016 in Bioscience Reports
Verified
Journal Article
Open access
PDF file
TMTomoji Maeda
Tomoji Maeda
MIManato Inagaki
Manato Inagaki
YFYu Fujita
Yu Fujita
TKTakehiro Kimoto
Takehiro Kimoto
CTChiaki Tanabe-Fujimura
Chiaki Tanabe-Fujimura
HKHiroto Komano
Hiroto Komano
The cerebral microcapillary endothelium, known as the blood–brain barrier (BBB), acts as a barrier between the blood and the interstitial fluid of the brain. The BBB therefore controls the passage of nutrients into the central nervous system (CNS). Microglia show a specific affinity for migration into the CNS, and this migration appears to occur independently of BBB integrity. To study the migration of microglia across the BBB, we developed an in vitro co-culture system of mouse brain endothelial cells (MBECs) and Ra2 microglia using Transwell inserts. We first investigated the influence of microglia or ATP, a microglial chemotactic factor, on MBEC barrier integrity. The addition of microglia or ATP led to the disruption of the MBEC monolayer and significantly decreased barrier function as measured by trans-endothelial electrical resistance (TEER) and electric cell–substrate impedance sensing (ECIS). Furthermore, ATP promoted the migration of microglia but not macrophages across the MBEC monolayer. An inhibitor of matrix metalloproteinases (MMPs) decreased the transmigration of microglia in our system, indicating that MMPs play a role in microglial chemotaxis. We specifically identify a role for microglia-derived MMP-2. In conclusion, we offer evidence that microglia migration across the brain endothelial cell monolayer is increased in the presence of ATP in a manner that involves MMP secretion.

26 February 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
LCLong-Yi Chan
Long-Yi Chan
CCCheng-Chung Chang
Cheng-Chung Chang
PLPo-Liang Lai
Po-Liang Lai
TMTomoji Maeda
Tomoji Maeda
HHHorng-Chaung Hsu
Horng-Chaung Hsu
Shu-Jui KuoShu-Jui Kuo
Shu-Jui Kuo
(1) Background: Inexplicable low back and neck pain frequently results from spinal disc degeneration with an imbalanced intervertebral disc (IVD) cell homeostasis. We hypothesize that introducing MSC expressing a sustained cartilage-anabolic factor in the IVD may stimulate the mucoid materials secreted from the IVD cells, promote the MSC’s chondrogenesis and maintain the hydration content providing mechanical strength to decelerate the disc degeneration progression; (2) Methods: This study expressed a cartilage-anabolic factor runx1 by a baculoviral vector (BV) transduced MSCs through a Cre/LoxP gene editing and recombination system for sustained recombinant runx1 transcription factor production. The Cre/LoxP BV modified MSCs were encapsulated by hyaluronan hydrogel, due to its’ vital composition in ECM of a healthy disc and transplanted to a punctured coccygeal disc in rats through micro-injection, followed by X-ray radiography and histological analysis at the 4- and 12-weeks post-transplantation; (3) Results: Data reveals the Cre/LoxP BV system-mediated long-termed runx1 gene expression, possessing good biosafety characteristics in the in vitro cell transduction and in vivo MSCs transplantation, and maintained superior hydration content in the disc than that of mock transduced MSCs; (4) Conclusions: This proof-of-concept study fulfills the need of implanting therapeutic cells accompanied with microinjection in the disc, such as a discography and paves a road to manufacture composite hyaluronan, such as peptide modified hyaluronan as an MSC carrier for IVD regeneration in the future study.

1 July 2017 in Neuroscience Letters
Verified
Journal Article
Closed access
YFYu Fujita
Yu Fujita
TMTomoji Maeda
Tomoji Maeda
KKKoji Kamaishi
Koji Kamaishi
RSRui Saito
Rui Saito
KCKoyo Chiba
Koyo Chiba
HKHiroto Komano
Hiroto Komano

1 May 2016 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
TMTomoji Maeda
Tomoji Maeda
CTChiaki Tanabe-Fujimura
Chiaki Tanabe-Fujimura
YFYu Fujita
Yu Fujita
CAChihiro Abe
Chihiro Abe
YNYoshino Nanakida
Yoshino Nanakida
HKHiroto Komano
Hiroto Komano

1 November 2015 in European Journal of Pharmacology
Verified
Journal Article
Closed access
TCTakeshi Chiba
Takeshi Chiba
TMTomoji Maeda
Tomoji Maeda
SKSoichiro Kimura
Soichiro Kimura
YMYasunori Morimoto
Yasunori Morimoto
ASAtsushi Sanbe
Atsushi Sanbe
KKKenzo Kudo
Kenzo Kudo